Instructions for SULFARGIN (Sulfacetamide) ointment
Pharmacological properties:
cUlfadiazine silver has an antimicrobial effect on gram-positive and gram-negative microbes and fungi ( Candida, Phycomycetes and Aspergillus spp , dermatophytes). The activity of the drug is due to the release of silver ions in the wound as a result of moderate dissociation of silver sulfadiazine, which achieves a long-term antimicrobial effect, which complements sulfadiazine (sulfanilamide). Silver ions are adsorbed on the surface of microbial cells and have the so-called oligodynamic bacteriostatic and bactericidal effect. The drug has no necrolytic and mutagenic effects. Sulfargin is characterized by moderate osmotic activity.
Pharmacokinetics:
When the ointment is applied to the wound, up to 1% of silver ions and up to 10% of sulfadiazine are absorbed. Most of the absorbed silver is excreted in the bile. Absorbed sulfadiazine does not accumulate in the body and is rapidly excreted by the kidneys.
SULFARGIN Indications:
Infected burns, bedsores
ulcers
superficial wounds with weak exudation
prevention of infection of burns
bedsores
ulcers
superficial wounds
abrasions, as well as during skin transplantation.
Application:
The drug is intended for topical use. An adequate regimen of application is selected after assessing the size and depth of the wound surface lesion.
After removal of necrotic tissue, the ointment is applied in a thin layer (2–4 mm) to the damaged area 1–2 times a day under a sterile dressing or in an open manner. Treatment lasts up to 3 weeks.
The method of administration and dose of the drug do not depend on the patient's age.
When using the ointment on an extensive wound surface, the function of the kidneys and liver and the number of blood cells should be monitored. The patient is shown an abundant alkaline drink.
Contraindications SULFARGIN:
Hypersensitivity to silver sulfadiazine, sulfonamides or to any excipient that is part of the drug. Genetic deficiency of glucose-6-phosphate dehydrogenase (hemolysis may occur when used in large areas). Due to the danger of nuclear jaundice, silver sulfadiazine should not be used in premature infants, newborns and children under 3 months of age. Silver sulfadiazine should not be used during pregnancy and breastfeeding.
Sulfargin is inappropriate to use for the treatment of deep purulent wounds and burn wounds with abundant exudation.
SULFARGIN Side effects:
- Local reactions
Rarely, the ointment can have a local irritating effect (short-term burning sensation, pain), which disappears after 5-10 minutes. With increased sensitivity, allergic reactions may occur - skin rash, burning sensation, itching, redness, allergic rhinitis or asthma. As a result of prolonged treatment or application on extensive wound surfaces of the skin, argyria may occur - as a result of the accumulation of silver in the tissues, the skin may acquire a slightly grayish color.
- Systemic reactions
With long-term treatment of extensive burn surfaces in the blood plasma, such concentrations of sulfonamides can be created, which are comparable to the concentrations achieved with systemic use.
Side effects characteristic of sulfonamides may occur: nausea, vomiting, diarrhea, glossitis, joint pain, liver damage, headache, confusion, convulsive spasms, crystalluria, kidney damage, leukopenia, thrombocytopenia, eosinophilia.
special instructions SULFARGIN:
Silver sulfadiazine should be used with caution in liver and kidney failure. If treatment with silver sulfadiazine is carried out for a long time or the drug is applied to extensive burn surfaces, then due to the risk of leukopenia, thrombocytopenia or eosinophilia, it is necessary to regularly determine the number of leukocytes in the blood
Avoid using the drug in patients with porphyria.
As with the topical use of other drugs with antimicrobial action, superinfection can also develop during the use of silver sulfadiazine.
Application in pediatrics. Due to the danger of nuclear jaundice, silver sulfadiazine should not be used in premature infants, newborns and children under 3 months of age.
Use during pregnancy and lactation. Studies on the safety of the use of silver sulfadiazine during pregnancy have not been conducted, therefore it should not be used during pregnancy and lactation.
Application in transport management and work with equipment. The drug does not affect the ability to drive vehicles and work with technical devices.
Interactions:
Silver sulfadiazine can inactivate agents for enzymatic wound cleansing, therefore, it is not recommended to use these drugs at the same time.
Overdose:
With prolonged treatment of extensive burn surfaces in the blood plasma, concentrations of sulfonamides can be achieved that are comparable to the concentrations achieved with systemic use, therefore, side effects associated with the systemic use of all sulfonamides, such as nausea, vomiting, diarrhea, glossitis, pain in joints, liver damage, headache, confusion, convulsive spasms, crystalluria, kidney damage, leukopenia, thrombocytopenia, eosinophilia. Treatment is symptomatic.
Storage conditions:
At a temperature not higher than 25 ° C. Do not store in refrigerator or freezer.
